In Vivo Alzheimer Proteomics (PROMARA)
Probable Alzheimer Disease, Parkinson Disease, Neurological Disease Without Cognitive Degradation
About this trial
This is an interventional diagnostic trial for Probable Alzheimer Disease focused on measuring Alzheimer disease (AD), diagnosis biomarkers, cerebrospinal fluid (CSF), targeted quantitative proteomics, mass spectrometry, stable isotope-labelled leucine
Eligibility Criteria
Inclusion Criteria:
- Reports written consent, informed and signed by the patient and a trusted person
- Subject member or beneficiary of a social security system
Specific criteria for group 1 and 2B :
- Age between 55 and 85 years old for patients
- Subject with AD or other neurodegenerative disease (frontotemporal dementia, dementia with Lewy bodies, Parkinson disease)
- Subjects with chronic adult hydrocephalus (HCA) requiring depletion lumbar puncture (PL)
Specific criteria for group 2A :
- Adult patient requiring neurosurgery with CSF shunt (subject with brain trauma, acute hydrocephaly) and favorable evolution that allows removal of the shunt
Exclusion Criteria:
- Patient deprived of liberty by judicial or administrative decision
- Major protected by law
- Pregnancy, women of childbearing age with risk of pregnancy, or breast-feeding
- Presence of a transmissible viral disease (HlV, hepatitis B and C)
- Patient included in a clinical trial
- lnadequate cardiac, hepatic or severe renal disfunction
- Disease amino acid metabolism (Leucinose..)
Exclusion Criteria:
- Information clinical and para-clinical insufficient or unavailable
- Patient deprived of liberty by judicial or administrative decision
- Major protected by law
- Pregnancy, women of childbearing age with risk of pregnancy, or breast
- feeding
- Presence of a transmissible viral disease (HIV, hepatitis B and C)
- Patient included in a clinical trial
- Patient exclusion period relative to another protocol or for which the maximum annual compensation of 4500€ has been reached
- Inadequate cardiac, hepatic or severe renal
- Disease amino acid metabolism (Leucinose..)
Sites / Locations
- Laboratoire de Biochimie et Protéomique Clinique, CHU Montpellier
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Group 1
Group 2A
Group 2B
60 patients (20 probable AD, 20 Parkinson Disease (PK), 20 neurological disease without cognitive degradation)
20 patients (patients with brain trauma, acute hydrocephaly), with temporary derivation of the CSF
30 patients (15 probable AD, 15 neurological disease without cognitive degradation)